Affiliation: Uppsala University Hospital
Hagström E, Michaelsson K, Melhus H, Hansen T, Ahlstrom H, Johansson L, et al
. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2014;34:1567-73 pubmed publisher
..Our data confirm and extend previous studies supporting a role for PTH in the development of atherosclerotic disease. ..
Hagström E, Hellman P, Larsson T, Ingelsson E, Berglund L, Sundstrom J, et al
. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765-71 pubmed publisher
..Further studies are warranted to evaluate the clinical implications of measuring PTH in cardiovascular risk prediction and to elucidate whether PTH is a modifiable risk factor. ..
HagstrÃ¶m E, AhlstrÃ¶m T, Ã„rnlÃ¶v J, Larsson A, Melhus H, Hellman P, et al
. Parathyroid hormone and calcium are independently associated with subclinical vascular disease in a community-based cohort. Atherosclerosis. 2015;238:420-6 pubmed publisher
..The findings indicate a possible link between the vasculature and mineral metabolism. ..
Hagström E, James S, Bertilsson M, Becker R, Himmelmann A, Husted S, et al
. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016;37:1325-33 pubmed publisher
..www.clinicaltrials.gov; NCT00391872. ..
Hagström E, Held C, Stewart R, Aylward P, Budaj A, Cannon C, et al
. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017;63:325-333 pubmed publisher
..Information on GDF-15, therefore, might be helpful when assessing the risk of adverse outcomes in patients with stable CHD. ClinicalTrials.gov Identifier: NCT00799903. ..